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Abstract
Background: The Sydney blood bank cohort (SBBC) of long-term survivors consists of multiple
individuals infected with nef-deleted, attenuated strains of human immunodeficiency virus type 1
(HIV-1). Although the cohort members have experienced differing clinical courses and now
comprise slow progressors (SP) as well as long-term nonprogressors (LTNP), longitudinal analysis
of nef/long-terminal repeat (LTR) sequences demonstrated convergent nef/LTR sequence evolution
in SBBC SP and LTNP. Thus, the in vivo pathogenicity of attenuated HIV-1 strains harboured by
SBBC members is dictated by factors other than nef/LTR. Therefore, to determine whether defects
in other viral genes contribute to attenuation of these HIV-1 strains, we characterized dominant
HIV-1 rev alleles that persisted in 4 SBBC subjects; C18, C64, C98 and D36.
Results: The ability of Rev derived from D36 and C64 to bind the Rev responsive element (RRE)
in RNA binding assays was reduced by approximately 90% compared to Rev derived from HIV-1NL4-
3, C18 or C98. D36 Rev also had a 50–60% reduction in ability to express Rev-dependent reporter
constructs in mammalian cells. In contrast, C64 Rev had only marginally decreased Rev function
despite attenuated RRE binding. In D36 and C64, attenuated RRE binding was associated with rare
amino acid changes at 3 highly conserved residues; Gln to Pro at position 74 immediately N-
terminal to the Rev activation domain, and Val to Leu and Ser to Pro at positions 104 and 106 at
the Rev C-terminus, respectively. In D36, reduced Rev function was mapped to an unusual 13
amino acid extension at the Rev C-terminus.
Conclusion: These findings provide new genetic and mechanistic insights important for Rev
function, and suggest that Rev function, not Rev/RRE binding may be rate limiting for HIV-1
replication. In addition, attenuated rev alleles may contribute to viral attenuation and long-term
survival of HIV-1 infection in a subset of SBBC members.
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Background
The Sydney blood bank cohort (SBBC) of long-term survi-
vors (LTS) consists of multiple individuals who became
infected with attenuated strains of human immunodefi-
ciency type 1 (HIV-1) via contaminated blood products
from a common blood donor between 1981 and 1984 [1-
3]. Long-term prospective studies showed convergent evo-
lution of nef/long-terminal repeat (LTR) sequences in
virus harbored by SBBC members, characterized by pro-
gressive sequence deletions toward a minimal nef/LTR
structure retaining only sequence elements required for
viral replication [4]. Thus, gross deletions in the nef/LTR
region of the HIV-1 genome contribute to viral attenua-
tion and slow progression of HIV-1 infection in SBBC
members. Despite convergent nef/LTR sequence evolu-
tion, after 22 to 26 years of infection SBBC members com-
prise antiretroviral therapy (ART)-naïve long-term
nonprogressors (LTNP) as well as slow progressors (SP)
who eventually commenced ART, suggesting that other
viral and/or host factors may contribute to the in vivo
pathogenicity (or lack thereof) of SBBC HIV-1 strains
[3,4].
Numerous viral and host factors have been shown to
affect the rate of HIV-1 disease progression [reviewed in
[5-7]]. Viral genetic factors other than nef/LTR associated
with SP or LTNP include mutations in the HIV-1 gag, rev,
vif,  vpr,  vpu  and  env  genes [8-13]. Host genetic factors
linked to a delay in the onset of AIDS and prolonged sur-
vival include the CCR5 Δ32 mutation, CCR2-V64I poly-
morphism, and certain HLA haplotypes [14-17].
HIV-1 Rev is a 116 amino acid (aa), ~18 kD regulatory
protein whose primary function is to mediate the nucleo-
cytoplasmic transport, and therefore expression, of
unspliced and singly spliced HIV-1 mRNA transcripts
encoding viral structural proteins, via binding to the Rev
response element (RRE) which is a complex RNA stem-
loop structure present in these transcripts [reviewed in
[[18-21]]. Therefore, Rev activity is essential for HIV-1 rep-
lication. Extensive mutational analysis of Rev has identi-
fied 2 distinct functional domains [reviewed in [21]].
These include an arginine-rich N-terminal region at aa
positions 34 to 50 which contains the nuclear localization
signal (NLS) and the RNA-binding domain (RBD) that
mediates direct binding of Rev to the RRE, and a highly
conserved leucine-rich C-terminal activation domain at aa
positions 75 to 83 which contains the nuclear export sig-
nal (NES). The N-terminal NLS/RBD is flanked on both
sides by less well defined sequences that are required for
multimerization [22-25].
A previous study of rev alleles isolated from a subject with
long-term nonprogressive HIV-1 infection showed a per-
sistent Leu to Ile change at position 78 in the activation
domain which attenuated Rev function and HIV-1 replica-
tion capacity [10], providing the first evidence that defec-
tive rev alleles may contribute to long-term survival of
HIV-1 infection in some patients. A subsequent study of
naturally occurring rev alleles with rare sequence varia-
tions in the activation domain showed variable reduc-
tions in Rev activity [26], although it was unclear from
this study whether the reductions in Rev activity observed
would be sufficient to attenuate HIV-1 replication capac-
ity. In the present study, we undertook a genetic and func-
tional analysis of HIV-1 rev alleles isolated from 4 SBBC
subjects to determine whether defects in viral genes other
than nef/LTR contribute to attenuation of HIV-1 strains
harbored by SBBC members.
Results and Discussion
Subjects
The clinical history of the study subjects, results of labora-
tory studies and antiretroviral therapies have been
described in detail previously [3,4,27]. The results of lab-
oratory studies relevant for the longitudinal samples used
in this study are summarized in Table 1. Briefly, D36
acquired HIV-1 sexually in December 1980. C18, C64 and
C98 acquired HIV-1 by receiving blood products donated
by D36 in August 1983, April 1983 and February 1982,
respectively. After 19 years of asymptomatic infection
without ART, D36 was placed on highly active ART
(HAART) in January 1999 after evidence of HIV-1 progres-
sion. C98 was also placed on HAART in November 1999
after 18 years of HIV-1 infection, and died of causes unre-
lated to HIV-1 in March 2001. C64 has been infected for
24 years without ART, and has stable CD4 T-cells and
below detectable viral load. C18 died of causes unrelated
to HIV-1 in November 1995, but prior to death was
asymptomatic with stable CD4 T-cell count for 12 years
without ART. Thus, D36 and C98 are SP, and C18 and
C64 are LTNP [3,4]. CCR5Δ32 genotyping by PCR
showed that all subjects carried CCR5 (wt/wt) alleles
([28], and J. S. Sullivan, personal communication).
CCR2-64I genotyping by PCR-RFLP showed that C64 and
C98 carried the CCR2-64I (wt/wt) genotype [28]. The
CCR2-64I genotype of C18 and D36 has not been deter-
mined.
Persistence of unique rev alleles in SBBC members
Peripheral blood mononuclear cells (PBMC) isolated
from blood samples longitudinally collected on 4 occa-
sions between 1995 and 2001 were available from D36,
C64 and C98 for this study (Table 1). Only one blood
sample collected in 1993 was available from C18. Blood
was taken from subjects in accordance with guidelines
endorsed by the Australian Red Cross Blood Service
human ethics committee. Multiple, independent full-
length Rev clones containing the first and second Rev cod-
ing exons were generated from genomic DNA of eachRetrovirology 2007, 4:43 http://www.retrovirology.com/content/4/1/43
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PBMC sample and sequenced. Phylogenetic analysis
showed that all Rev sequences were clade B (data not
shown). The dominant Rev aa sequence from each PBMC
sample, which represents the consensus sequence from 10
independent clones, is shown in Additional file 1. In each
subject where longitudinal PBMC samples were available
(D36, C64 and C98), the persistence of a dominant rev
allele was evident over a 4- to 6-year period. Figure 1
shows an aa sequence alignment of these dominant and
persistent rev alleles as well as the dominant rev allele in
the single C18 PBMC sample. Single aa changes at posi-
tions 74, 104, 106, 108 and 112 in sequence encoding Rev
exon 2 segregated the dominant C18 and C98 Revs from
the dominant C64 and D36 Revs. However, each domi-
nant Rev sequence contained unique, distinguishing aa
changes. In addition, C18, C64 and C98 Revs had a 3 aa
extension at the Rev C-terminus, and D36 Revs had a 13
aa extension at this position. Similar C-terminal exten-
sions were not identified in 164 Rev sequences available
in the Los Alamos data base and other published studies
[10]. Thus, the dominant and persistent Revs harbored by
these SBBC members are unique. The following studies
functionally characterized Rev proteins derived from
these dominant and persistent SBBC rev alleles.
Rev proteins derived from subjects C64 and D36 have 
attenuated RRE binding capacity
The ability of His-tagged Rev proteins derived from the
dominant and persistent SBBC rev alleles to bind the RRE
was quantified by electrophoretic mobility shift assays
with [32P]-labelled RNA transcripts bearing the RRE (Fig.
2A). His-tagged Rev and Matrix proteins derived from
HIV-1NL4-3 were used as positive and negative controls,
respectively. Compared to His-tagged Rev from HIV-1NL4-
3, the ability of His-tagged Revs from D36 and C64 to
form Rev/RRE complexes at non-saturating Rev concen-
trations (0.25 μM) was reduced by approximately 90%
(Fig. 2B). In contrast, the ability of His-tagged Revs from
C18 and C98 to form Rev/RRE complexes at non-saturat-
ing Rev concentrations was similar to His-tagged Rev from
HIV-1NL4-3. These results indicate that Rev proteins
derived from the dominant and persistent D36 and C64
rev alleles have attenuated ability to bind the RRE.
Rev amino acid sequences associated with attenuated RRE 
binding
Attenuated RRE binding was not due to mutations in the
N-terminal RBD, since the amino acid sequences across
this region were conserved among all SBBC rev alleles and
were identical to HIV-1NL4-3 (Fig. 1). This was somewhat
surprising, since previous studies showed that the RBD of
Rev was the principal determinant of RRE binding [23-
25,29-32]. The C-terminal 3 aa extensions present in C18,
Table 1: Subjects, longitudinal blood samples and corresponding laboratory studies.
Subject Date infected Date of blood
sample
CD4+ T-cellsa 
(cells/μl)
Viral load b 
(RNA copies/
ml)
HIV-1 
progression 
statusc
No. Rev clones 
sequencedd
D36 12/1980. 5/1995 N/A 1400 SP 10
1/1997 367 3200 10
7/1999 N/A BD 10
4/2001 476 BD 10
C18 8/1983 12/1993 809 N/A LTNP 10
C64 4/1983 8/1996 925 BD LTNP 10
8/1997 805 BD 10
4/1999 1026 BD 10
5/2000 875 BD 10
C98 2/1982 10/1995 576 670 SP 10
2/1997 629 770 10
11/1999 646 690 10
5/2001 527 760 10
a; CD4+ T-cells were measured by flow cytometry.
b; Plasma HIV-1 RNA was measured by COBAS Amplicor HIV-1 Monitor Version 1.0 (Roche Molecular Diagnostic Systems, Branchburg, N.J.) prior 
to July 1999 and Version 1.5 after July 1999. HIV-1 RNA levels < 400 copies/ml (Version 1) or < 50 copies/ml (Version 1.5) were considered below 
detection.
c; The clinical status of the subjects has been described in detail previously [3, 4, 27].
d; The consensus sequences of the 10 Rev clones sequenced from each time point are shown in Additional file 1.
BD, below detection; N/A, not available; SP, slow progressor; LTNP, long-term nonprogressor.Retrovirology 2007, 4:43 http://www.retrovirology.com/content/4/1/43
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C64 and C98 Revs (Fig. 1) had no effect on RRE binding,
since RRE binding by C18 and C98 Revs was similar to
HIV-1NL4-3. Three amino acid changes that were conserved
among D36 and C64 rev alleles and that were not present
in C18 and C98 rev alleles were identified outside the
RBD; Gln to Pro at position 74 immediately N-terminal to
the Rev activation domain, and Val to Leu and Ser to Pro
at positions 104 and 106 at the Rev C-terminus, respec-
tively (Fig. 1). Amino acid changes also occurred at posi-
tions 108 and 112 which segregated C64 and D36 Revs
from C18 and C98 Revs, but database analysis showed
that amino acid variation is frequent at these positions
(data not shown). Thus, amino acid changes at positions
108 and 112 are not likely to affect Rev/RRE binding. In
contrast, the clade B consensus residues Gln-74, Val-104
and Ser-106 are normally highly conserved, with residue
frequencies of 0.90, 0.94 and 0.97, respectively (Table 2).
Pro-74, Leu-104 and Pro-106 are rare amino acid changes
among clade B Revs; Only 16 rev  alleles from 164
sequences available in the Los Alamos data base and other
published studies [10] had Pro-74, Leu-104 or Pro-106,
with individual residue frequencies of 0.049, 0.018 and
0.018, respectively (Table 2). The frequency of any 2 of
these residues being present was 0.006. None of the avail-
able sequences had all 3 amino acid changes. Thus, the
amino acid changes occurring in D36 and C64 Revs are
unique. However, the presence of one or more of these
amino acid changes was not able to discriminate between
subjects with progressive or non-progressive HIV-1 infec-
tion (Table 2). Moreover, none of these amino acid
changes occurred in a previously identified LTNP with
defective rev alleles [patient MA [10], Table 2]. Thus, the
contribution of any or all of these mutations to decreased
RRE binding by D36 and C64 Revs, and possibly to slow
or absent HIV-1 progression, is likely to be context
dependent. Further mutagenesis studies are required to
determine the contribution of Pro-74, Leu-104 or Pro-106
to diminished RRE binding by these Rev variants.
Rev is a highly structured protein [reviewed in [20,21]].
Biochemical and structural studies identified an α-helix at
aa 8 to 26, and another at aa 34 to 59 spanning the NLS/
Amino acid sequences of persistent and dominant SBBC rev alleles Figure 1
Amino acid sequences of persistent and dominant SBBC rev alleles. The HIV-1 Rev amino acid sequences shown rep-
resent those derived from the dominant and persistent rev alleles harboured by SBBC subjects C18, C64, C98 and D36. They 
are the consensus sequences of multiple independent Rev clones that persisted over a 4- to 6-year period in C64, C98 and 
D36, or which were dominant in a single blood sample obtained from C18 [see Additional file 1]. Amino acid alignments are 
compared to Rev from HIV-1NL4-3. Dots indicate residues identical to HIV-1NL4-3 Rev, and dashes indicate gaps. Boxed residues 
indicate amino acid substitutions which discriminate C18 and C98 Revs from C64 and D36 Revs. NLS; nuclear localization sig-
nal, RBD; RNA binding domain, NES; nuclear export signal.Retrovirology 2007, 4:43 http://www.retrovirology.com/content/4/1/43
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RBD, separated by a Pro-rich region at aa 27 to 39, which
folds into a helix-loop-helix structure where intramolecu-
lar contacts between the 2 α-helices are facilitated by
hydrophobic interactions [reviewed in [20]]. The Rev RBD
within the latter α-helix interacts specifically with an
internal loop of the RRE through major groove interac-
tions [33]. The C-terminal region of Rev is thought to be
more flexible. However, a discontinuous epitope of a Rev-
specific monoclonal antibody was mapped to aa 10 to 20
and 95 to 105 by protein foot printing, suggesting that the
α-helices are in close proximity to the Rev C-terminus
[34,35], and suggesting a role for the C-terminus in stabi-
lizing native Rev structure. Thus, aa changes occurring at
the Rev C-terminus or elsewhere such as Pro-74, Leu-104
and/or Pro-106 could potentially affect Rev structure and
thus, Rev/RRE binding. Proline provides exceptional con-
formational rigidity to proteins. Thus, It is possible that
Pro-74 and/or Pro-106 may impede RRE binding by alter-
ing native Rev structure.
Rev derived from D36, but not C64, has impaired function
To determine whether SBBC Revs have impaired function,
D36, C64, C18 and C98 Revs were subcloned into the
pcDNA3.1 expression vector. Western blot analysis of Rev
protein expression using sheep polyclonal anti-Rev antise-
rum showed equivalent levels of Rev in lysates of trans-
fected CEM cells (Fig. 3A). Rev function in mammalian
cells was investigated using the Rev-dependent reporter
plasmid pDM128 [31], which expresses the chloram-
phenicol acetyltransferase (CAT) gene in the presence of
Rev, as described previously [36] (Fig. 3B). In this assay,
the Rev expression plasmids were first titrated to deter-
mine an amount to use that was within the linear
response range of the assay (data not shown). Levels of
CAT activity were compared to those present in lysates of
cells co-transfected with pDM128 and HIV-1NL4-3 Rev.
Cells cotransfected with pDM128 and empty pcDNA3.1
vector or pcDNA3.1 expressing HIV-1NL4-3 Matrix protein
were included as negative controls. Levels of CAT activity
Analysis of Rev/RRE binding Figure 2
Analysis of Rev/RRE binding. RNA binding assays were conducted with [32P]-labelled RRE riboprobes and increasing con-
centrations of His-tagged Rev proteins, as described in Materials and Methods. Binding reactions containing increasing concen-
trations of His-tagged Matrix protein from HIV-1NL4-3 were included as negative controls. Rev/RRE complexes were resolved 
by electrophoresis in 5% (wt/vol) native polyacrylamide gels and visualized by autoradiography (A). Bands were quantified by 
phosphorimager analysis, and the percentage of RNA binding was calculated by dividing the signal intensity of bands associated 
with Rev/RRE complexes by the signal intensity of all bands, and multiplying this number by 100 (B). The data shown are repre-
sentative of three independent experiments. *p < 0.01, Student's t test.Retrovirology 2007, 4:43 http://www.retrovirology.com/content/4/1/43
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in lysates of cells transfected with C18 or C98 Revs were
not significantly different to those in lysates of cells trans-
fected with HIV-1NL4-3 Rev. In contrast, levels of CAT activ-
ity in lysates of cells transfected with C64 or D36 Revs
were reduced by approximately 20% and 50%, respec-
tively (P < 0.01). Similar results were obtained using 293
cells (data not shown). In addition, similar results were
obtained using a Rev-dependent HIV-1 env reporter sys-
tem as a measure of Rev function, as described previously
[37] (data not shown). These data suggest efficient Rev
function by C18 and C98 Revs, a modest reduction in the
activity of C64 Rev, but significant impairment in the
activity of D36 Rev.
Amino acid sequences associated with impaired D36 Rev 
function
Efficient C18 and C98 Rev function is consistent with
results of the Rev/RRE binding studies that showed effi-
cient RRE binding by these Revs (Fig. 2). However, the
modest or significant impairment in C64 or D36 Rev
activity, respectively, is discrepant with results of the Rev/
RRE binding studies that showed equivalent reductions in
RRE binding by these Rev variants (Fig. 2). Therefore, in
C64 Rev, the reduced levels of RRE binding appear to be
sufficient for the majority of Rev function to be retained.
Additional sequence changes that differentiate C64 and
D36 Revs are likely to impair D36 Rev function. Longitu-
dinal sequence analysis showed that the presence of an
unusual 13 aa extension at the D36 Rev C-terminus was
the only genetic alteration that consistently differentiated
D36 Rev from C64 Rev (Fig. 1), [see also Additional file
1]. The otherwise isogenicity of the D36 and C64 Revs
used in the functional studies identifies the C-terminal 13
aa extension as the primary determinant underlying
impaired D36 Rev function.
It is presently unclear how this sequence alteration may
affect D36 Rev function, but the additional 13 aa at the
Rev C-terminus may affect Rev structure. One hypothesis
is that such structural changes may interfere with the
recruitment of cellular proteins to the NES such as eIF-5A
[38], nucleoporins including Rip/Rab [39-43] and CRM1/
exportin 1 [44-46], which could potentially affect nuclear
export. The presence of Pro at position 74 immediately N-
terminal to the Rev NES may induce further structural
changes contributing to this interference, which might
also account for the modest reduction in C64 Rev activity.
Further studies are required to fully elucidate the impor-
tance of amino acid alterations that impair D36 Rev func-
tion.
Table 2: rev alleles with rare Pro-74, Leu-104 and/or Pro-106 mutationsa
Clade B HIV-1 
strain or Rev 
clone
Residue at position: (Clade B consensus residue; 
frequencyb)
Frequency of 
residue 
combinationb
Status of HIV-1 
progressiond
GenBank 
accession no.
Reference
74 (Gln; 0.90) 104 (Val; 0.94) 106 (Ser; 0.97)
C64 Pro Leu Pro unique LTNP EF634155 This report
D36 Pro Leu Pro unique LTS EF634154 This report
MAc Gln Val Ser 0.884 LTS N/A Iversen et al., [10]
C42 Pro Val Ser 0.049 N/A AF538305 Unpublished
D31 Pro Val Ser 0.049 N/A U43096 Kreutz et al., [48]
UKR1216 Pro Val Ser 0.049 N/A AF193278 Liitsola et al., [49]
NY5CG Gln Leu Ser 0.018 AIDS M38431 Willey et al., [50]
89.6 Pro Val Ser 0.049 AIDS U39362 Collman et al., [51]
WEAU160 Pro Leu Ser 0.006 N/A U21135 Unpublished
1299_d22 His Val Pro 0.018 N/A AY308761 Bernardin et al., 
[52]
1006_08 Pro Val Ser 0.049 Acute infection AY331284 Bernardin et al., 
[53]
1058_08 Pro Val Ser 0.049 Acute infection AY331294 Bernardin et al., 
[53]
PRB959_03 Gln Val Pro 0.018 Acute infection AY331296 Bernardin et al., 
[53]
RU128005 Gln Val Pro 0.018 N/A AY682547 Unpublished
98USHVTN3605c
9
Pro Val Ser 0.049 N/A AY560108 Unpublished
PCM013 Glu Leu Ser 0.018 N/A AY561237 Unpublished
50333-03 Gln Leu Ser 0.018 LTS U30750 Iversen et al., [10]
931395-04 Pro Val Ser 0.049 AIDS U30775 Iversen et al., [10]
LA-09 Gln Leu Pro 0.006 AIDS U30785 Iversen et al., [10]
a; Sixteen of 164 Clade B HIV-1 rev sequences screened from the Los Alamos National Laboratory HIV Database and other published studies [10] contained Pro-74, Leu-104 
and/or Pro-106 mutations. Underlined boldface indicates the presence of one or more of these rare amino acid changes.
b; Amino acid frequency was calculated by dividing the number of sequences with the amino acid, or the particular amino acid combination, by the total number of sequences 
analyzed (n = 164).
c; Patient MA, identified as a LTS with attenuated rev alleles in a previous study by Iversen et al., [10] was included for comparison.
d; LTNP, long-term nonprogressor; LTS, long-term survivor; AIDS, acquired immune deficiency syndrome; N/A, not available.Retrovirology 2007, 4:43 http://www.retrovirology.com/content/4/1/43
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Conclusion
In this study, we demonstrate reduced capacity of persist-
ent and dominant Rev variants isolated from a subset of
SBBC members to bind the RRE, which was associated
with unique rev alleles carrying rare amino acid substitu-
tions at 3 highly conserved positions outside the RBD; Gln
to Pro at position 74 immediately N-terminal to the Rev
activation domain, and Val to Leu and Ser to Pro at posi-
tions 104 and 106 at the Rev C-terminus, respectively.
However, decreases in Rev/RRE binding per se were not
sufficient to attenuate Rev function. This conclusion is
supported by studies of C64 Rev, which had significantly
reduced RRE binding but only modestly reduced Rev
function. Additional sequence changes present in D36
Rev attenuated Rev function. This was mapped to an unu-
sual 13 aa extension at the Rev C-terminus, which was the
only genetic change that distinguished C64 and D36 rev
alleles. This genetic alteration may alter structural proper-
ties of Rev that are required for optimal Rev function.
Together, our data suggest that Rev function, not Rev/RRE
binding may be rate limiting for HIV-1 replication.
It is presently unclear whether attenuated D36 Rev func-
tion in vitro equates to attenuated Rev function in vivo, and
indeed whether attenuated Rev function contributed to
slow progression of HIV-1 infection in this subject.
Extrapolation of these in vitro findings to an in vivo role for
attenuated D36 rev alleles is difficult, since this subject
and other SBBC members are infected with virus contain-
ing gross nef/LTR deletions which have been shown to
contribute significantly to viral attenuation in this cohort
[1,4,27]. Furthermore, the attenuated properties of D36
and C64 Revs did not distinguish SBBC LTNP from SP. In
fact, among the SBBC subjects studied here, D36 had the
most attenuated rev alleles yet the most progressive HIV-1
infection, suggesting that any effect that attenuated rev
alleles may have in vivo is likely to be dependent on other
viral and/or host factors. Nonetheless, our results support
those of a previous study that showed attenuated Rev
function in an asymptomatic individual [10], and those of
another study that showed reduced Rev function among
rev  alleles with naturally occurring sequence variations
[26], raising the possibility that attenuated Rev function
may contribute, at least in part, to viral attenuation and
slow HIV-1 progression in D36. However, in contrast to
these studies where attenuated Rev function was mapped
to mutations in the activation domain [10,26], attenuated
Rev function in D36 was mapped to the Rev C-terminus.
In sum, these findings provide new genetic and mechanis-
tic insights important for Rev function. In addition, atten-
uated rev alleles may contribute to viral attenuation and
long-term survival of HIV-1 infection in a subset of SBBC
members. A better understanding of viral determinants
other than nef/LTR that contribute to HIV-1 pathogenicity
(or lack thereof) in SBBC members may provide addi-
tional mechanistic insights important for controlling HIV-
1 infection in vivo.
Methods
Rev cloning and sequencing
Full-length HIV-1 Rev clones containing the first and sec-
ond Rev coding exons were generated from genomic DNA
of patient PBMC samples by PCR using Expand high fidel-
ity DNA polymerase (Roche Diagnostics, Basel, Switzer-
land) as follows; The first Rev coding exon was amplified
using primers 5RevE2 (5'-GGGTGTCGACATAGCA-
GAATAG-3'; corresponding to nt positions 5781 to 5802
of HIV-1NL4-3) and 3RevE2 (5'-CTGCTTTGATAGA-
GAAGCTTG-3'; corresponding to nt positions 6024 to
6044 of HIV-1NL4-3) that spans a SalI restriction site 5' to
the Rev start codon. The second Rev coding exon was
Analysis of Rev protein expression and function in mamma- lian cells Figure 3
Analysis of Rev protein expression and function in 
mammalian cells. Rev function was examined by co-trans-
fection of CEM cells with pcDNA3.1-Rev plasmid and the 
Rev-dependent pDM128 CAT expression plasmid [31], as 
described in Materials and Methods. Cells co-transfected 
with pDM128 and pcDNA3.1 expressing HIV-1NL4-3 Matrix 
protein or empty pcDNA3.1 vector were included as nega-
tive controls. Rev protein expression was determined by 
Western blotting with sheep anti-Rev polyclonal antisera (A). 
CAT activity in cell lysates was quantified and normalized to 
CAT activity in lysates of CEM cells co-transfected with 
pDM128 and NL4-3 Rev (B). Values shown are means of trip-
licate transfections. Error bars represent standard deviations. 
Results are representative of three independent experi-
ments. *P < 0.01, Student's t test.Retrovirology 2007, 4:43 http://www.retrovirology.com/content/4/1/43
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amplified using primers 5RevE3 (5'-CCACCTCCCAATC-
CCGAGGGG-3'; corresponding to nt positions 8371 to
8391 of HIV-1NL4-3) and 3RevE3 (5'-CTAGGTCTCGAGA-
TACTGCTC-3'; corresponding to nt positions 8879 to
8898 of HIV-1NL4-3) that spans an XhoI restriction site 3' to
the Rev stop codon. To avoid sequence resampling, six
independent PCRs of Rev exon 1 or Rev exon 2 coding
sequence were pooled prior to 3-way ligation in pGEM
(Promega, Madison, WI) using SalI and XhoI restriction
sites and blunt end ligation to link the Rev exon 1 and Rev
exon 2 coding sequences.
Ten independent Revs cloned from each PBMC sample
were sequenced using a SequiTherm EXCEL II DNA
sequencing kit (Epicenter Technologies, Madison, WI)
and a model 4000L LI-COR DNA sequencer (LI-COR, Lin-
coln, NE). Predicted aa sequences were deduced from
nucleotide sequences, and aligned and analyzed using
DNAMAN software (Lynnon, Quebec, Canada).
Rev/RRE binding assays
His-tagged Rev proteins derived from SBBC rev  alleles
were produced, purified and quantified using the pET bac-
terial expression system (Novagen, Madison, WI), accord-
ing to the manufacturers' protocol. The ability of His-
tagged Rev proteins to bind the RRE was quantified by
electrophoretic mobility shift assays with [32P]-labelled
RNA transcripts bearing the RRE, as described previously
[47]. Briefly, binding reactions consisted of excess [32P]-
labelled RNA and increasing concentrations of His-tagged
Rev protein (0, 0.05, 0.25, 0.40 or 0.50 μM) in 10 μl bind-
ing buffer [10 mM HEPES/KOH (pH 7.6), 150 mM KCl, 2
mM MgCl2, 0.5 mM EGTA, 1 mM dithiothreitol, 20%
(vol/vol) glycerol, 3.2 μg E. coli tRNA]. Reactions were
incubated on ice for 10 min, then applied to 5% (wt/vol)
nondenaturing polyacrylamide gels containing 100 mM
Tris borate (pH 8.3), 1 mM EDTA, and 3% (vol/vol) glyc-
erol and run at 4°C followed by autoradiography and
phosphorimager analysis.
Rev function assays
To facilitate Rev protein expression in mammalian cells,
SBBC  rev  alleles were subcloned into the pcDNA3.1
expression vector (Invitrogen, Carlsbad, CA). Rev func-
tion in mammalian cells was quantified using the Rev-
dependent reporter plasmid pDM128, which expresses
the CAT gene from an intron bearing the RRE in the pres-
ence of HIV-1 Rev [31]. Briefly, CEM cells were cotrans-
fected with 4.0 μg pDM128, 0.75 μg pcDNA.1-Rev
plasmid and 0.25 μg pEGFP plasmid to control for trans-
fection efficiency. The Rev expression plasmids were
titrated first to determine an amount to use that was
within the linear response range of the assay (data not
shown). After minor volume adjustments for small varia-
tions in transfection efficiency, cell lysates were prepared
at 72 h post-transfection and assayed for CAT activity as
described previously [36].
Western blot analysis
Lysates were prepared from CEM cells that were trans-
fected as described above, separated in 12% (wt/vol) SDS-
polyacrylamide gels, and transferred to nitrocellulose
membranes, as described previously [37]. Blots were
probed with a 1:500 dilution of sheep anti-Rev polyclonal
antisera (ICN). Rev proteins were visualized using horse-
radish peroxidase-conjugated anti-sheep immunoglobu-
lin G antibody and enhanced chemiluminescence
(Promega).
Nucleotide accession numbers
The  rev  nucleotide sequences reported here have been
assigned GenBank accession numbers EF634153 to
EF634156.
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